EZZ Life Science Holdings (ASX:EZZ) Altman Z2-Score: 14.25 (As of Aug. 02, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EZZ EZZ Life Science Holdings Ltd ASX:EZZ
49 GF Score
Price A$0.48
GF Value A$1.45
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is EZZ Life Science Holdings Altman Z2-Score?

EZZ Life Science Holdings ASX:EZZ +3.23% 49 Altman Z2-Score is 14.25 as of Aug. 02, 2026, which is 4% above its 10-year median of 13.64. GuruFocus rates ASX:EZZ with a GF Score™ of 49/100 and a GF Value™ of A$1.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,388 Biotechnology companies, EZZ Life Science Holdings ranks better than 88.4% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

EZZ Life Science Holdings has a Altman Z2-Score of 14.25, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for EZZ Life Science Holdings's Altman Z2-Score or its related term are showing as below:

ASX:EZZ' s Altman Z2-Score Range Over the Past 10 Years
Min: 7.06   Med: 13.64   Max: 15.13
Current: 14.25

During the past 6 years, EZZ Life Science Holdings's highest Altman Z2-Score was 15.13. The lowest was 7.06. And the median was 13.64.


EZZ Life Science Holdings  (ASX:EZZ) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


EZZ Life Science Holdings Altman Z2-Score Related Terms


EZZ Life Science Holdings Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for EZZ Life Science Holdings's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EZZ Life Science Holdings Altman Z2-Score Chart

EZZ Life Science Holdings Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Altman Z2-Score
Get a 7-Day Free Trial 13.57 11.40 13.70 15.13 14.25

EZZ Life Science Holdings Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 15.13 0.00 14.25 0.00

ASX:EZZ vs VRTX, REGN, RVMD: Altman Z2-Score Comparison

For the Biotechnology subindustry, EZZ Life Science Holdings's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EZZ Life Science Holdings Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where EZZ Life Science Holdings's Altman Z2-Score falls into.


ASX:EZZ
49GF Score
EZZ Life Science Holdings Ltd ASX:EZZ
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EZZ Life Science Holdings Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

EZZ Life Science Holdings's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.8043+3.26*0.5689+6.72*0.3119+1.05*4.7837
=14.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2025:
Total Assets was A$33.96 Mil.
Total Current Assets was A$33.04 Mil.
Total Current Liabilities was A$5.73 Mil.
Retained Earnings was A$19.32 Mil.
Pre-Tax Income was A$10.59 Mil.
Interest Expense was A$-0.01 Mil.
Total Liabilities was A$5.87 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(33.038 - 5.726)/33.957
=0.8043

X2=Retained Earnings/Total Assets
=19.318/33.957
=0.5689

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(10.586 - -0.006)/33.957
=0.3119

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(28.085 - 0)/5.871
=4.7837

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

EZZ Life Science Holdings has a Altman Z2-Score of 14.25 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 14.25 mean?
EZZ Life Science Holdings (ASX:EZZ) has a Altman Z2-Score of 14.25 as of Aug. 02, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on EZZ Life Science Holdings and its competitors. This is near median its historical median of 13.64. Over the past decade, EZZ Life Science Holdings' Altman Z2-Score has ranged from 7.06 to 15.13. According to the industry distribution chart, EZZ Life Science Holdings ranks #161 out of 1388 companies in the Biotechnology industry, placing it in the top 11.6%.
Is EZZ Life Science Holdings' Altman Z2-Score too high?
EZZ Life Science Holdings' current Altman Z2-Score of 14.25 is near median its 10-year median of 13.64. Over the past 10 years, this metric has ranged from a low of 7.06 to a high of 15.13. Based on the distribution chart, EZZ Life Science Holdings ranks #161 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #161 out of 1388 companies for Altman Z2-Score. This places EZZ Life Science Holdings in the top 12% of its industry — outperforming the majority of peers. Historically, EZZ Life Science Holdings' own Altman Z2-Score has ranged from 7.06 to 15.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on EZZ Life Science Holdings and its competitors. EZZ Life Science Holdings's current Altman Z2-Score is 14.25, which is near median its own 10-year median of 13.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.45, compared to a current price of A$0.48 — trading 66.9% below its estimated fair value. The current Altman Z2-Score is 14.25, which is near median its 10-year median of 13.64. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current Altman Z2-Score is 14.25 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?

Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued. The current stock price of A$0.48 is trading 66.9% below its estimated GF Value™ of A$1.45. GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.

Key valuation signals for ASX:EZZ:

  • Altman Z2-Score: 14.25 (near median its 10-year median of 13.64)
  • GF Value™: A$1.45 vs. price of A$0.48 (66.9% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EZZ Life Science Holdings Business Description

Address 55-59 Parramatta Road, Shop 1, Lidcombe, NSW, AUS, 2141
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score

Get the complete analysis for ASX:EZZ

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price
A$1.45
GF Value